Chemokine CCR3 antagonists
Source: Expert Opinion on Therapeutic Patents, Volume 10, Number 9, September 2000 , pp. 1455-1459(5)
Publisher: Informa Healthcare
Six applications from SmithKline Beecham and Roche that claim novel small molecule CCR3 receptor antagonists are discussed. These applications describe three distinct structural classes of antagonist. Three applications from SmithKline Beecham describe ester, amide and hydrazide derivatives of 2-aroylamino-3-phenylpropanoic acid. Roche’s applications describe derivatives of 1-(1-[4-benzoyl)piperidin-1-ylmethyl]-2-methylpro- pyl)-3-arylureas and derivatives of N-(1-benzylpyrrolidin-3-yl)methyl-1-(5- phenylpyrimidin-2-yl)propanamide. These compounds are claimed to be useful in the treatment of asthma and other inflammatory conditions.
Document Type: Miscellaneous
Publication date: September 1, 2000